FREMONT, Calif.--(BUSINESS WIRE)--DiscoveRx continues to innovate in field of GPCR signaling assays, tools and services and now has the largest and most comprehensive portfolio of assays and reagents for non-force coupled GPCR analysis. With a portfolio of over 300 validated assays for known and orphan GPCRs along with HitHunter™ second messenger and PathHunter™ ß-Arrestin assays and services, drug discovery researchers have expedited their GPCR drug discovery. The company expects key publications and announcements in various meetings and releases that reaffirms the value of the portfolio in GPCR drug discovery and research.
